ENV-308 Clears First Human Trial in 88 Adults as Exercise-Mimicking Obesity Pill Shows Safety
Updated
Updated · Women's Health · Aug 21
ENV-308 Clears First Human Trial in 88 Adults as Exercise-Mimicking Obesity Pill Shows Safety
3 articles · Updated · Women's Health · Aug 21
Summary
Phase 1 data in 88 healthy adults showed ENV-308 was well tolerated, with no serious side effects and no dropouts, marking the first human safety test for the daily oral obesity drug.
The pill is designed to mimic Lac-Phe, a hormone released during intense exercise and after meals that suppresses appetite, aiming to capture those effects longer than the natural molecule can.
Researchers also reported an "exceptional" gastrointestinal safety profile and lower circulating leptin, though the trial was not built to measure weight loss or improved leptin sensitivity.
Doctors said ENV-308 remains years from market and cannot replace exercise or GLP-1 drugs yet, because human data on actual weight loss, muscle preservation and use in obese patients are still missing.